Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aardvark Therapeutics, Inc. ( (AARD) ) has shared an announcement.
On February 9, 2026, Aardvark Therapeutics, Inc. reorganized key leadership roles as Chief Operating Officer Bryan Jones, Ph.D., transitioned to become Chief Executive Officer of its new wholly owned dermatology subsidiary, Ardia Therapeutics, Inc., and current Chief Financial Officer Nelson Sun was appointed to also serve as Chief Operating Officer. Under a letter agreement linked to his role change, Jones waived severance rights, received clarified salary and health benefit protections tied to his Ardia tenure, secured continued exercisability of existing Aardvark stock options while employed at Ardia, and obtained accelerated vesting of certain equity awards.
On February 12, 2026, the company announced Ardia’s formation to advance a new dermatology pipeline centered on lead topical asset DIA-615 for inflammatory skin diseases, including psoriasis, with Jones appointed to lead the business and build its portfolio. The same day, Aardvark also disclosed the expansion of Sun’s remit as dual CFO/COO and the appointment of Derrick C. Li as Chief Business Officer, moves that collectively signal a bid to sharpen strategic focus on both Aardvark’s metabolic franchise and Ardia’s dermatology programs while preserving continuity in corporate operations and business development leadership.
The most recent analyst rating on (AARD) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Aardvark Therapeutics, Inc. stock, see the AARD Stock Forecast page.
Spark’s Take on AARD Stock
According to Spark, TipRanks’ AI Analyst, AARD is a Neutral.
The score is held back primarily by weak financial performance (pre-revenue, widening losses, and substantial cash burn implying funding risk). Offsetting factors include favorable technical momentum (price above major moving averages with positive MACD) and positive corporate pipeline milestones (Phase 3 HERO trial progress and updated program communications), while valuation remains constrained by ongoing losses and a negative P/E.
To see Spark’s full report on AARD stock, click here.
More about Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel small-molecule therapeutics that activate innate homeostatic pathways to treat metabolic diseases and hunger-associated conditions. Its lead oral compound, ARD-101, is in Phase 3 development for hyperphagia in Prader-Willi syndrome, and the company is also advancing ARD-201 in Phase 2 trials targeting limitations of existing GLP-1 obesity therapies.
Ardia Therapeutics, Inc., a wholly owned U.S. subsidiary of Aardvark, is focused on DIA-615, a clinic-ready topical drug candidate for inflammatory skin diseases such as psoriasis. DIA-615 is designed to localize in the skin and act on TAS2R GPCRs in inflammatory cells to downregulate stressed endoplasmic reticulum and reduce skin lesions associated with severe dermatologic conditions.
Average Trading Volume: 204,052
Technical Sentiment Signal: Strong Buy
Current Market Cap: $274.6M
Learn more about AARD stock on TipRanks’ Stock Analysis page.